Disrupting the BTN3A1–BTN2A1 B30.2 association could potentially inhibit the activation of Vγ9Vδ2 T cells by natural pAgs, which would have implications for treatments of autoimmune diseases associated with γδ T cells. The gene discussed is BTN2A1; the disease is autoimmune disease.